Vetoquinol is launching Cimalgex, a new NSAID for dogs this month.
Cimalgex (cimicoxib) is a new second generation COX-2 inhibitor which can be used for the treatment of pain and inflammation due to osteoarthritis and the management of peri-operative pain associated with orthopaedic and soft tissue surgery, for which it can be given two hours before surgery and continued for 3-7 days post surgery.
Vetoquinol says that an important consideration in treating dogs with osteoarthritis, many of which are geriatric, is that there are no contraindications to using Cimalgex in patients with mild to moderate renal impairment.
According to the company, field trials showed that over 90 per cent of per owners and vets identified that animals experienced excellent analgesia post operatively*.
Available in a chewable, splitable tablet, Cimalgex can be given with or without food.
Vetoquinol says that the excellent tolerability, efficacy profile and ease of use of Cimalgex means that veterinary patients could benefit from pain relief in situations where clinicians are worried about the risks versus the benefits of prescribing a NSAID for pain management.
Further information about assessing pain and decision making when it comes to prescribing NSAIDs, will be presented in a free webinar on 19th October at 8.30pm. To register go to www.thewebinarvet.com/vetoquinol and enter code CIM1.
Reference*E. Grandemange: Field evaluation of the efficacy and the safety of cimicoxib in the relief of peri-operative pain in dogs; 2008, study number n°3008C2F1
Axiom Veterinary Laboratories has launched SLIT - sublingual immunotherapy treatment - for allergies in cats, dogs and horses.
According to the company, sublingual immunotherapy has been shown to be safe and effective in humans for over 20 years and a recent study has shown it to be a beneficial alternative way of administering immunotherapy to cats, dogs and horses, proving particularly effective in treating animals that failed to respond to allergy shots.
Patients can convert from shots to drops with an initial treatment kit.
Martyn Carpenter, Director of Axiom Laboratories Ltd, said: "Each ACTT Allergy Drop prescription is a custom formulation containing the specific allergens that are causing the pet's discomfort. Allergy drops are prepared in a glycerin solution to provide antigen stability, and have a slightly sweet taste, which assists in palatability and ease of administration. This method greatly reduces irritation and the likelihood of anaphylactic shock and can be administered easily at home by the client, freeing up consult slots and removing the stress which accompanies a visit to the surgery for many pets. This can be a particularly suitable alternative for those clients on a restricted budget, for whom on-going consult and injecting fees can be prohibitive to compliance with immunotherapy treatment. "
For more information, contact Axiom's Diagnostic Support Team on 01626 355655
In a separate statement, Mr Stevens said: "Anything that gives homeopathy a veneer of credibility risks chancers being able to con more people into parting with their hard-earned cash in return for bogus treatments which at best do nothing, and at worst can be potentially dangerous."
One of the dangers Mr Stevens referred to was the "rise in misinformation about vaccines - some of which is apparently promoted by homeopaths - and which poses a significant danger to human health."
In other words, anyone gullible enough to believe that a dilution of 1,000,000,000,000 parts of water to one part of crude oil, or skimmed milk, or human placenta, or condoms, or anything else for that matter, is going to cure them of anything, is more likely to believe all sorts of anti-vaccine, anti-pharmaceutical company nonsense, something which is very dangerous at a time when vaccination rates have been declining.
Human medicine does not have the monopoly on nonsense, of course. There are those who continue to peddle the lie that homeopathy can cure cancer in animals, and as the declining rates of human vaccination would tend to suggest, no shortage of people prepared to believe them.
Niall Taylor MRCVS, author of No Way To Treat a Friend, said: "The situation in the veterinary profession mirrors that in the medical profession: a small number of people preaching the benefits of a discredited belief system to vulnerable people.
"Some in the profession argue that we should humour those owners who practise homeopathy in animals, as to challenge them would drive them underground. The problem is that if we don't challenge them, we help foster a belief system which doesn't just harm animal health, but human health too. So the skill here is to find ways to challenge these beliefs in a way that is empathetic and constructive."
However, despite keeping this POM-V drug to hand, only 7% said they would seek advice for minor wounds and over 25% said they would not contact the vet even if their horse was lame.
This, says the company, raises concerns about the appropriate use of bute in wounded horses and suggests that practices should be providing first aid training for horse owners, covering basic wound management and when to seek veterinary advice.
The survey, which was posted on social media groups for horse owners, showed they were most likely to call out a vet if their horse had a deep wound (96% of respondents). However, only a third would seek veterinary advice for a wound that is bleeding.
Vita, which makes the veterinary-exclusive Omnimatrix skin cream, said that 84% of owners keep a topical treatment for minor wounds in their first aid box, but some use barrier creams that do not provide an antiseptic environment.
Tara Evans RVN, Head of Sales at Vita, said: "It is great to see that owners are equipped with a first aid box for their horses. However, our survey highlights that many are not seeking veterinary advice, even if their horse is lame. This raises concerns over horses receiving appropriate treatment in a timely manner. There is an opportunity for practices to review first aid boxes with owners to ensure they're stocking appropriate supplies, and discuss appropriate wound management."
Vita has created an owner guide for wound management in horses which you can download and give to clients, here: https://www.vita-europe.com/animalhealth/news/wound-healing-in-horses/
Concern has been expressed in the profession about environmental contamination from products used in companion animal treatment for ectoparasites, such as fleas and ticks.
In recent years there has been a widely documented fall in the abundance of many terrestrial invertebrate populations1.
While the decline has been mostly linked to agricultural chemicals, there is a concern that companion animal ectoparasiticides could also be a contributing factor, with a recent study2 confirming the presence of common compounds used in flea-treatment3 in UK waterways.
However, the association with companion animal ectoparasiticides is currently poorly understood, with a significant knowledge gap and little robust research available to assess the true importance and environmental consequences.
The funded project ‘Assessing the Environmental Risk from Ectoparasite Treatments in Companion Animals’ will be led by Professor Richard Wall, Professor of Zoology and Dr Emily Bell, Senior Lecturer at University of Bristol in collaboration with Dr Imogen Schofield, Veterinary Statistician and Epidemiologist at CVS, and Lizzie McLennan-Green, Small Animal Veterinary Director at CVS.
It will be conducted via a PhD studentship at the University of Bristol as part of the CVS Clinical Research Awards.
The research will include a longitudinal ‘citizen science’ study with pet owners to develop a greater understanding of owner use and attitudes towards ectoparasiticides.
It will also include laboratory assessments of ectoparasiticide residues collected from companion animals to provide evidence-based information on the potential environmental impact of the treatments when applied to companion animals.
It is hoped the study will help the wider veterinary profession develop the most appropriate approaches to prescribing and use of ectoparasiticides in the future, and inform educational strategies to support owners with ‘responsible use’. The study is also set to benefit companion animals, as the research will inform strategies to ensure the most appropriate control of parasitic burden to pets.
The project starts in January 2023 and will run for three-years as a full time PhD.
CVS is providing £95,000 to fund the research.
References
The 12-module programme is aimed at European veterinary professionals who have completed their General Practitioner Certificate in Diagnostic Imaging (GPCertDIIM) or Postgraduate Certificate (PgC) in Diagnostic Imaging and who wish to advance their diagnostic imaging skills further and build on their academic qualifications.
The GPAdvCert in Diagnostic Imaging (CT) will be delivered in three blocks of four days in three European cities and will be led by Course Director Tim Trevail BVetMed, CertVDI, DipECVDI, MRCVS.
The course starts in May 2019 with training taking place in Vienna (Austria), Porto (Portugal) and Limassol (Cyprus).
Each module will be led by ECVS or ACVS Diplomates and will be supported by an online learning platform providing notes, additional resources and the ability for delegates to discuss clinical cases in a closed forum.
The programme has received conditional validation from Harper Adams University pending full approval early next year and is accredited by the European School of Veterinary Postgraduate Studies (ESVPS).
David Babington MRCVS, Business Development Director at Improve International, said: "Diagnostic Imaging (CT) is already widely available in many veterinary practices, with Diagnostic Imaging and CT studies becoming more and more common for veterinary practitioners as a result. Each module of this advanced programme has been designed to progress delegates’ knowledge beyond Postgraduate Certificate level with more in-depth and advanced content. The programme focuses on practical training and includes CT scan reading sessions and case discussions."
He added: "Improve’s GPAdvCert programmes help vets in practice to reduce the number of patients they refer, enabling them to retain a higher level of income for their practice. The programme will also provide them with skills which they can pass onto their team."
For more information visit www.improveinternational.com or email enquiries@improveinternational.com or call 01793 759159.
This, says the government, would be one of the toughest sanctions in Europe, strengthening the country's claim to be a global leader on animal welfare.
The Animal Welfare (Sentencing) Bill comes after a public consultation held last year which found that more than 70% of people supported proposals for tougher prison sentences. It will allow the courts to take a tougher stance on things like dog fighting, puppy and kitten abuse, and neglect of farm animals.
The new Bill has been welcomed by animal welfare charities.
Chief Executive for the RSPCA, Chris Sherwood, said: "This reform is long overdue. Those responsible for extreme cruelty towards animals or those criminal gangs involved in organised animal crime will now face the tough justice they deserve.
"We need to better protect our animals and the RSPCA hopes that this new Animal Welfare (Sentencing) Bill will give courts the powers they need to punish those responsible for the most unimaginable cruelty to animals.
"We also believe this will act as a much stronger deterrent to others and help us stamp out animal cruelty once and for all."
James Yeates, Cats Protection’s Chief Executive said: "We very much welcome this announcement which is an important step in ensuring the UK is one of the world leaders on animal welfare issues.
Claire Horton, Chief Executive of Battersea Dogs & Cats Home, said: "The introduction of this bill is a landmark achievement, which will make a profound difference to dogs and cats in England and Wales."
Mr Wood faced three charges, all relating to allegations of misconduct over a laboratory test for an alpaca while he was working at a practice in South Oxfordshire.
The charges alleged that in September 2023, Mr Wood told the alpaca’s owner that it had tested positive for Johne’s disease when in fact, the animal had not been tested.
He then allegedly sent a letter confirming a positive test result for the test that had not taken place, and then created a false test result report in the name of a veterinary surgeon colleague and sent it to another colleague by email.
He later told the alpaca's owner that he had given her the wrong result by mistake and that the test result was actually negative.
Then in October 2023, he emailed the laboratory saying that a member of his practice’s administrative staff had written the false report.
In November he told the managing partner of his then employer on three occasions that he was investigating the false report in order to find out who sent it.
Finally, he sent a misleading and dishonest email to a veterinary surgeon colleague falsely indicating that a member of the practice’s staff had manufactured the false report, when that was not the case.
At the outset of the hearing Mr Wood admitted the facts of all the allegations against him.
Having found the facts proven, the Committee found that the charges amounted to serious professional misconduct, something which Mr Wood himself also admitted.
The Committee identified a number of aggravating factors in Mr Woods' conduct, including his lack of honesty, probity and integrity, the fact the conduct was premeditated, that it involved a breach of the client’s trust, the abuse of his professional position, the fact the conduct was sustained and repeated over a period of time, and that his conduct contravened advice given by the RCVS.
The mitigating factors included positive testimonials from professional former colleagues and client farmers, the fact that he had engaged in some remediation in order to avoid repeating the dishonest behaviour, and that he showed significant insight into his misconduct.
Dr Neil Slater MRCVS, chairing the Committee and speaking on its behalf, said: “The Committee recognised that the serious repeated dishonesty, which was to conceal wrongdoing, made the respondent’s misconduct particularly serious.
“It therefore gave consideration as to whether his conduct was fundamentally incompatible with being a veterinary surgeon and whether removal was the only appropriate and proportionate sanction in this case.
“The Committee considered that this was a particularly difficult case to reconcile, as, on the one hand the misconduct was so serious whereas on the other hand, the respondent had demonstrated significant insight; the risk of repetition was low; the evidence of his professional achievements was strong and the testimonials from client farmers and professional colleagues were impressive.”
He added: “The Committee considers that suspension is sufficient in the circumstances of this case to satisfy public confidence in the profession and to uphold proper professional standards of conduct and behaviour.
"The Committee therefore imposes a suspension of 18 months on the respondent.
"In determining this length, the Committee considered that this was the least period necessary in order to meet the significant public interest considerations in this case.”
https://www.rcvs.org.uk/concerns/disciplinary-hearings
RCVS Council agreed, in principle, to the sale of Belgravia House and for the College and its London-based staff to move to different premises at its November meeting.
The sale of the building and the move will be overseen by the College’s Estate Strategy Project Board headed by former RCVS President Barry Johnson and including current and former RCVS Council members and RCVS staff.
The RCVS has been based at its current premises in 62-64 Horseferry Road for 25 years, but says it now needs more up-to-date and modern facilities to accommodate a projected increase in the number of staff.
The College says it has considered a number of alternatives, including expanding the current premises by adding or expanding floors. However, due to the fact that the building is in a conservation area, it has become clear that any such expansions would be unlikely to get planning permission from Westminster Council.
Lizzie Lockett, RCVS Chief Executive, said: "For a number of years it has become apparent that it is fast approaching the time at which our current premises will no longer be fit for purpose due to an increase in the number of RCVS staff – something that is projected to continue in the future – the ongoing need to use the building for Disciplinary Hearings, which take over the lion’s share of available meeting space, and the need for better and more modern facilities.
"Even putting our need for increased space on one side, Belgravia House requires major refurbishment in key areas such as air-conditioning and lifts, which would require staff to vacate the premises for up to 18 months, which would be costly and disruptive.
"We are therefore pleased that Council has recognised the need for the College to move somewhere that better reflects our needs and, over the coming months, we will be exploring a number of different options for new premises.
"In parallel to this we have put out an invitation to tender for agents to manage the sale of the building. The plan is for the arrangement to include lease-back so that we have time to find a suitable premises and enabling us to act quickly when we do."
Any organisations that are interested in putting forward a tender to manage the sale of the building should contact Corrie McCann, RCVS Director of Operations, on 020 7202 0724. Responses to tender are required by 30 November 2018.
Photo: Copyright Google 2018
Carprodyl Quadri is a pork-flavoured, four-way break tablet, available in two presentations of 50mg and 120mg. Each tablet offers four dosage strengths, designed to help you prescribe more accurately for a dog’s weight with fewer boxes on the shelves.
Part tablets can be kept in the blister pack for up to 72 hours, so clients can take home the exact amount of carprofen they require, thereby reducing cost and waste.
To support the launch of Carprodyl Quadri, Ceva is launching a range of marketing materials for veterinary practices. They include: dosage charts, dispensing envelopes, remember to order stickers to stick on boxes left on the shelves, reminder cards about the change for reception and dispensaries and client letters explaining why their prescription has changed.
Lucy Vernon, product manager at Ceva Animal Health said: "Carprodyl Quadri is an easy to administer carprofen that provides accurate dosing while reducing cost and waste and is a welcome addition to our popular pain management portfolio."
For further information, contact your local Ceva Animal Health territory manager.
Allegations were reported both in The Times, and the Veterinary Record.
In its statement, the College said: "We know that the University of Edinburgh takes any such accusations extremely seriously and that its inquiry fully and robustly investigated the claims in 2019. This inquiry found no evidence of misconduct, a decision that was later upheld after an appeal.
The College recognised the massive impact that bullying can have on anyone who has been subject to it and acknowledged that the individual accounts published in the Veterinary Record were upsetting to read. However it also drew attention to the 'huge amount of stress that can be caused by ‘trial by media’, especially when an inquiry has concluded that there were no issues to be found'.
As to the role of the RCVS Junior Vice-President, the College pointed out that this is a matter for RCVS Council, as the postholder is elected by Council.
Professor Argyle will be making a statement to Council at its next meeting on 5th November, after which Councillors will be able to ask any questions they have, and then consider the matter.
Meanwhile, the College has asked the Vet Record whether any of the people who made the anonymous testimonials would like to supply any information directly.
Chanelle has announced the launch of Ketamidor 100 mg/ml Solution for Injection (ketamine), licensed for use in cats, dogs, horses, cattle and swine in the UK and Ireland.
The company says the new product provides a versatile addition to anaesthetic regimes. It can be used in combination with other widely-used anaesthetics and sedatives. Chanelle says it also has analgesic properties that make it particularly beneficial to include in anaesthetic protocols when carrying out painful surgical procedures.
Ketamidor 100mg/ml Solution for Injection has a zero day withdrawal period for milk and meat when used in cattle and pigs, allowing high welfare standards to be maintained without compromising economic returns.
According to Chanelle, ketamine is now experiencing a resurgence of interest as its analgesic properties and minimal impact on spontaneous respiration become increasingly appreciated.1
Angela Wilkin, Chanelle UK's Sales and Marketing Manager said: "Ketamidor makes a great addition to our portfolio of pain management products. Our territory managers are looking forward to speaking to those vets who are already accustomed to using ketamine and those that may be considering adding it to their current protocols."
Reference
The British Veterinary Association's Animal Welfare Foundation has produced an online advice leaflet to guide veterinary surgeons through the possible scenarios in the consulting room.
'The practical and legal approach to the docked puppy' leaflet answers questions like:
Introducing the leaflet BVA AWF Chair Tiffany Hemming said: "With such complex and varying laws on tail docking of dogs this leaflet provides clear guidance for vets on how to handle the first consultation with a docked puppy.
"The leaflet includes an easy to follow flow-chart and aims to help vets tackle the subject without alienating their clients."
You can view the leaflet here.
Protexin says Pro-Kolin Advanced contains beneficial micro-organisms, several prebiotic sources, an optimal level of a dual-source binding agent and soothing fibres to support gastrointestinal function.
The company also says that in a study involving 148 dogs, Pro-Kolin Advanced significantly improved clinical outcome compared to a placebo1.
Protexin Veterinary Director, James Kyffin, said: "Pro-Kolin Advanced represents an exciting development for Protexin Veterinary and fits in perfectly with our ethos to produce innovative, research-based products of the highest quality for pets.
"It is the first product of its kind to be supported by a randomised, controlled clinical trial that was undertaken in first opinion veterinary practices across the UK and Ireland.
"Not only are we pleased to be able to offer veterinary surgeons with an evidence-based option for the management of acute gastrointestinal disturbances, but also a very palatable formulation that was readily accepted by 92% of the dogs in the study."
Pro-Kolin Advanced is available in 15ml, 30ml and 60ml syringes for dogs and 15ml syringes for cats. The flavourings used in the product contain no proteins or common allergens so Pro-Kolin Advanced can be used in animals with known hypersensitivities.
VetSurgeon is sad to report that Sam Duff, a much loved figure in the profession, died last weekend.
Sam qualified from Edinburgh in 1970, and was a partner in mixed practice in Fife until 2002. More recently, he was a director of Equitique Ltd, an equine reproduction referral practice.
Sam was an active member of BVA Council, and its Member Services Group. He served on SPVS Council from 1993-2002, and was re-elected in 2003. He had recently been elected as Secretary of the Scottish branch of the BVA.
A memorial service will be held at 2.30pm on Thursday 9th July in Younger Hall, St Andrews.
The RCVS has announced that it is carrying out an audit of continuing professional development (CPD) for vets in order to monitor compliance and gauge what type of activities they are engaging in.
Under the RCVS Code of Professional Conduct, introduced in 2012, veterinary surgeons are expected to undertake 105 hours of CPD over a rolling three-year period in order to demonstrate that they are maintaining and advancing their knowledge and skills.
Nearly 5,000 vets - made up of three cohorts - have been asked to share their CPD records. The first cohort comprises 4,425 UK-practising vets who registered before 1 April 2012 but who did not confirm their CPD compliance upon renewing their registration this year. The second cohort comprises a random sample of 400 vets who did confirm their compliance upon renewing their registration this year. The third cohort comprises 84 vets who graduated before 2012 but have not yet completed their post-graduation Professional Development Phase.
Christine Warman, RCVS Head of Education, said: "Since it is coming up to three years since we introduced the Code we thought that now is a good time to take stock of the proportion of veterinary surgeons that are fulfilling the requirement and how they are doing so.
"It is also a good time to remind members of the profession of the importance of CPD and that it is not just a tick-box exercise but vital for everyday practice. Engaging in CPD is a personal obligation for all veterinary surgeons and demonstrates to both the profession and public that they are continually advancing their capability and competence.
"This year we will be providing some guidance on what constitutes CPD and how to undertake it to those who are non-compliant. However, from 2015, we may also refer those who repeatedly fail to comply, or respond to requests to submit their records, to our Professional Conduct Department for further investigation."
Vets who have been selected to take part in the audit will have received letters in early November and will have until Monday 1 December to respond. They can do so by either allowing the RCVS to view their online Professional Development Record (PDR) profile or by submitting their paper CPD record by post or by sending the College a scanned copy by email.
For further advice and to submit a CPD record by email, contact cpd@rcvs.org.uk. Those who have not yet registered for the PDR can do so by visiting www.rcvs-pdr.org.uk
Clinicians at the Queen Mother Hospital for Animals at the Royal Veterinary College have become the first team in the UK to successfully treat acromegaly in a cat with hypophysectomy surgery.
According to the RVC, this make it the first centre in the UK, and only the fourth in the world, to offer this procedure. The patient groups that might benefit from this RVC-exclusive procedure include cats and dogs with non-functional pituitary tumors, cats and dogs with hyperadrenocorticism (Cushing's disease) and cats with acromegaly or hypersomatotropism.
The RVC says removing the pituitary gland and the associated tumour which causes acromegaly or hyperadrenocorticism is the gold standard treatment in humans suffering from these diseases since it offers the greatest chance of a complete cure for the disease.
Prior to the RVC offering surgical treatment, the only treatment options available for acromegalic cats in the UK were radiation therapy or simply treatment of the resulting diabetes mellitus. The latter can prove extremely difficult and frustrating and the former unpredictable, unreliable and/or ineffective. Even when a complete response to the radiation therapy eventually occurs, hormonal abnormalities usually persist.
Dr Stijn Niessen, leading the hypophysectomy team at the Royal Veterinary College, said: "I'm extremely proud to be able to offer this unique surgery for the first time in the UK at the RVC. As a relatively new and innovative procedure in veterinary medicine there are risks involved, as is recognised with every form of neurosurgery of this level. However, despite these risks, this surgery does offer owners a chance for the best possible result for their pet using a single procedure. Hypophysectomy therefore represents the most elegant treatment method currently available enabling complete removal of the brain tumor and normalisation of damaging excessive hormone levels that are causing hormonal diseases like acromegaly and hyperadrenocorticism.
"Especially when a pituitary tumor is diagnosed late, the alternative treatment method of radiation therapy might well take too long to take effect and devastating neurological signs might occur due to the pressure of the pituitary tumor on the surrounding brain. In such cases, hypophysectomy can make an instant difference in relieving that pressure. However, in general, we would advocate the procedure to be considered as soon as possible following diagnosis, thereby preventing the animal's body from becoming more and more negatively affected by the excessive hormone levels associated with pituitary diseases like acromegaly and hyperadrenocorticism."
Dr. Niessen, a European Veterinary Specialist in Internal Medicine with research interests in diabetes and endocrinology and world-expert in acromegaly, will be selecting the patients suitable for the new treatment, preparing them for surgery and managing the aftercare programme. The longer-term aftercare programme will include hormone replacement treatment administered through eye-drops (usually temporarily) and tablets (permanent) to manage the hormone production lost through removal of the pituitary gland.
The surgery itself will be performed by Patrick Kenny, a European and American Specialist in Veterinary Neurology and Neurosurgery.
The RVC says the surgery would not be possible without the multidisciplinary approach at the Queen Mother Hospital for Animals, which includes the Internal Medicine, Neurology and Neurosurgery, Diagnostic Imaging, Anaesthesia and Emergency and Critical Care teams as well as a team of highly qualified nurses.
To support ongoing research in this field, the Royal Veterinary College is offering free blood tests for all diabetic dogs and cats which include fructosamine evaluation and screening tests for the presence of acromegaly in cats. Cats that record high hormone levels indicative of acromegaly will qualify to undergo a free CT scan for confirmation. If acromegaly is confirmed, all possible treatment options will be discussed with the client, including the hypophysectomy procedure. To request a free blood test for a patient please visit: www.rvc.ac.uk/cic
Veterinary surgeons currently managing a cat or dog with a pituitary tumor who are considering referral of this case can also contact Dr Stijn Niessen for further information at the QMHA on 01707 666365 or at qmhreception@rvc.ac.uk
Novartis Animal Health UK Ltd has announced the launch of CLiKZiN Pour On for sheep, a short meat withhold period (MWP) product that can be used throughout Spring and Summer for the prevention of blowfly strike in sheep and lambs.
CLiKZiN is a ready-to-use water-based product that protects sheep for eight weeks, and has a meat withhold period of seven days. The product is a line extension of CLiK which offers a longer period of protection at 16 weeks and has a longer withhold period of 40 days. Novartis says that used in conjunction with CLiK, CLiKZiN offers versatile protection throughout the year.
The launch of CLiKZiN comes at the same time that Vetrazin has been reformulated, resulting in a longer meat withhold period for sheep treated with the product.
Thomas Tiley MRCVS from Novartis Animal Health said: "Farmers need reliable protection from the repugnant threat of blowfly strike. CLiKZiN provides eight weeks blowfly prevention together with the trusted performance and safety record associated with CLiK. It also offers the greater flexibility of a seven day meat withhold.
"This makes CLiKZiN ideally suited for a variety of production schedules and stock including lambs for slaughter and pre-shearing ewes."
Blowfly strike can be devastating to sheep, causing severe impact on the welfare of the animal. Within days of a blowfly laying its eggs, clinically normal sheep can be afflicted with flesh eating maggots. This makes prompt and effective treatment critical.
National Sheep Association Chief Executive Peter Morris said: "Fly strike is a terrible burden to the sheep industry both in terms of the welfare of the sheep and economically.
"Having a product available that gives effective prevention against fly strike whilst at the same time having a withdrawal period which does not impinge on the ability of the sheep farmer to market lambs is very welcome. The sheep farmers' armoury against the every day afflictions which affect sheep has been significantly enhanced."
All practices are eligible to register and no FCA authorisation is needed.
Carefree Credit says it will also process applications to make practice administration hassle free.
Mike Aldred, Director at Carefree Credit, said: "With the deepening cost of living crisis, owning a pet has never been more expensive for many pet owners and having these longer terms available will really help their pets get the treatment they need."
To register your practice with Carefree Credit, email office@carefreecredit.co.uk or call 0345 313 0177.
https://www.carefreecredit.co.uk
The procedure was performed in Canada through an international collaboration between partners from Germany, Canada and the UK, who say that this was a case where the placement of the tumour made it impossible to operate without severely impacting the dog’s quality of life. The most suitable treatment was a total excision of the growth and reconstruction with an implant.
The implant was designed with medical CAD tools by German company, Voxelmed, using 3D imaging from the affected area. The dog's veterinary surgeon, Julius Liptak, contributed to the design to ensure it met specifications and allowing him to plan the procedure in advance.
UK company Renishaw then additively manufactured the patient specific implant (PSI) at the Additive Design In Surgical Solutions (ADEISS) Centre in London, Ontario, Canada.
Ed Littlewood, Marketing Manager at Renishaw’s Medical and Dental Products Division said: "Without the advancements in additive manufacturing technology, this dog would not have had such a long and happy future ahead of him.
"Prior to this case, many veterinary surgeons were unaware that the technology was available. Similar procedures are now being planned in Germany and further research is underway to see how animals can benefit from additively manufactured PSIs.
Jan Klasen, veterinary surgeon, 3D designer and CEO of Voxelmed said: "Without AM technology, it would have been almost impossible to reconstruct the dog’s maxilla after tumour removal, because the area was extremely complex in geometry. The implant had to have a similar shape and functionality as the dog’s existing bone structure.
"Using additive manufacturing to maintain the original shape and function of the oral and nasal cavity ensures a high quality of life for the dog, just as a naturally shaped skull and maxilla helps the dog to breathe and eat easily."
To read the full case study, visit http://www.renishaw.com/en/additive-manufacturing-in-veterinary-surgery-saving-a-well-loved-member-of-the-family--42950.
The College says the speed and accuracy of scans produced by the new scanner will revolutionise the treatment of animals at the Queen Mother Hospital for Animals (QMHA). It also reduces the need for animals to be anaesthetised before being scanned, with most patients now only requiring partial sedation.
The new scanner has been named the 'Otter Scanner' after a patient of the RVC whose owner was made a significant donation towards the RVC's charity, the Animal Care Trust, which funded the new machine.
Professor Dan Chan, Professor of Emergency and Critical Care Medicine and Medical Director of the QMHA at the RVC, said: "It is very uncommon that such an incredible leap in the care of animals can be achieved with a single innovation.
"Because of the vast improvement in speed and quality of the images produced by the ‘Otter Scanner’ our specialists are now able to obtain much more detailed images of various diseases affecting our patients so that the best possible treatment can be planned.
"At the RVC, one of our most important missions is to always improve the welfare and care of animals and this latest innovation is just another example of that commitment. We are forever grateful to all our supporters who have made this possible."
The publishers say that with a global donkey population estimated at around 46 million, it’s imperative for the veterinary profession to stay well-informed about the unique biology and disease susceptibility of this species.
The virtual collection addresses the previous shortfall of pathophysiological information, with articles on pharmacology, diagnostics, disease prevalence and management practices relating to donkeys as working, companion and production animals.
Preventative healthcare is addressed with a study of a companion population of donkeys in the UK and clinicians are encouraged to focus on client education, promotion of vaccination, regular dental care, strategic parasite control programmes and weight management.
Several papers address decision-making around treatment options, emphasising the need for a good understanding of the pharmacology of the available therapeutic agents in relation to donkeys and the pathophysiology of the diseases, as well as the value of pain assessment and control.
Another important aspect of disease detection and management is the availability of accurate diagnostics. Several papers address aspects of diagnostic testing, with emphasis on the caution that must be taken when extrapolating from horses because of the minimal data relating specifically to donkeys.
Donkeys are often described as silent carriers of, or as being more resistant to, infectious agents. Two articles demonstrate that they can in fact develop severe clinical signs when exposed to certain known equine pathogens, raising the importance of surveillance, accurate diagnosis, outbreak management, disease control and clear communication and education.
Less common conditions in donkeys as well as awareness of zoonotic risk are addressed within the collection, emphasising the value of owner-driven reporting as part of a disease surveillance and control programme to inform decision making on relevant interventions.
Professor Celia Marr, Editor of the EVJ, said: “This impressive collection shines a spotlight on the important advances that have been made to donkey medicine and welfare and helps us to identify the research gaps yet to be filled
“By sharing this work, we aim to improve disease prevention and enhance the welfare of donkeys around the world as well as highlight the continued importance of owner education and improve the public perception of this enduring species.”
The virtual issue can be found here: https://beva.onlinelibrary.wiley.com/doi/toc/10.1001/(ISSN)2042-3306.donkey-medicine-welfare.vi
Bordetella bronchiseptica is a clinically significant pathogen for canine infectious respiratory disease (CIRD), otherwise known as kennel cough, with 78.7% of dogs with acute respiratory signs testing positive for the bacteria1.
In the same study, 45.6% of clinically healthy dogs also tested positive for Bordetella bronchiseptica, illustrating that clinically healthy dogs can carry respiratory pathogens and could act as sources of infection for susceptible dogs1.
Administered via subcutaneous injection, Canigen Bb is an inactivated subunit vaccine which offers vets a new option when intra-nasal vaccination with a live aerosolised vaccine is not possible or preferred, for example when the dog is in contact with known immunocompromised individuals.
Licensed for use in dogs from 6 weeks of age, Canigen Bb extends protection against Bordetella bronchiseptica in dogs vaccinated with Canigen KC in the last 12 months for a further year with a single dose.
Canigen Bb is presented as a ready-to-use formula in a 10ml multi-dose bottle and can be stored at room temperature (2°C - 25°C) for up to 4 weeks once broached.
It can be administered concurrently (at the same time but separate injections) with Canigen DHP, Canigen DHPPi, Canigen Pi & Canigen Lepto 4.
Andrew Connolly, Marketing Director at Virbac, said: ‘It is our hope that Canigen Bb will increase the overall uptake of Bordetella bronchiseptica vaccination to provide increased protection against this widely prevalent and clinically significant disease’.
According to the charity, every year, 250,000 animals are brought to rescue centres around the UK1. Most are much loved pets that through no fault of their own find themselves without a home. They may be an odd mix of breeds, they may not look perfect, but they have so much to give.
Battersea’s research shows that whilst 92% of people say they believe rescue is the right thing to do2, when the time comes to get a new pet, many choose to go online and search for a specific breed instead. In the last 12 months there have been on average 165,000 monthly searches online for ‘French Bulldogs’3. A fifth of people who say they wouldn’t consider rescue say they can’t get the type of breed they want from a rescue centre4 and over half (52%) say the animals in rescue centres often have health or behavioural problems, and you don’t know their full history5.
Claire Horton, Battersea’s Chief Executive, said: "Even though one in four dogs and cats are rescues6, you’re still more likely to hear about French Bulldogs, or Labradors being the nation’s favourite pets. Our preoccupation with breed is fuelling a ruthless pet trade based on looks alone – one that can sadly put profit before animal welfare."
"Battersea is setting out to increase the visibility of rescue animals, to show they’re more common than you think, and are in homes across the nation. They’re the most rewarding, responsible choice for a pet, and we’re hoping to bring them front of mind – to get all generations of animal lovers to think rescue first."
To encourage potential pet owners to be more open to rescue pets and look beyond certain breeds, Battersea has removed breed filters from its own online animal galleries. Initial tests have shown that when visitors to the site were not given the option to filter by breed, they viewed more animal profiles, and a higher percentage of them went on to apply to rehome a dog or cat.
Rob Young, Battersea’s Head of Operations, said: "We know that misconceptions and pre-conceived notions about the traits and behaviours of certain dog and cat breeds can heavily influence people’s rehoming choices. By removing the option to search by breed we’re hoping that visitors to our website will be more open-minded to finding the right match. If someone is looking for an affectionate lap dog, or an energetic, playful pet, then they will find a perfect match regardless of breed. When you go to Battersea, you won’t just get a Ragdoll, or a Labrador, or even a Mongrel. Most importantly, you’ll be getting a Rescue."
Last year Battersea rehomed 2,301 dogs and 2,140 cats. The charity says it has seen a notable reduction in rehoming over recent years as more people search online for fashionable breeds and are influenced by what they see on social media. The charity believes ‘Rescue Is Our Favourite Breed’ will help break down some of the misconceptions people have about rescue animals, encouraging them to see rescue as desirable and a badge of honour.
Rob added: "People think rescue dogs or cats will be harder to train than a puppy or kitten, or that it’s just not as prestigious to own a pet that hasn’t come from a breeder. Well, nothing could be further from the truth. Ask any proud rescue owner and they will tell you that rescue pets are the best pets. They may not be perfect, but they’re worth it."
For more information on the campaign, visit Battersea.org.uk and join the growing community of rescue lovers at #RescueIsMyFavouriteBreed.
Tim took over the role from Renate Weller at the end of BEVA Congress last week. Lucy Grieve, of Rossdales Veterinary Surgeons became President Elect.
After leaving Bristol in 1989, Tim worked in mixed practice before joining Bell Equine in 1993, becoming a partner in 1995. He led the hospital services at Bell Equine, as well as supervising the practice’s residency, intern and extern programmes, until it was bought by CVS in 2016. He continues to work as a clinician at Bell Equine whilst also working as the Equine Veterinary Director of CVS.
Tim is an RCVS Specialist in both equine internal medicine and equine soft tissue surgery and is a founding diplomate of the European College of Equine Internal Medicine; he became an Associate of the European College of Veterinary Diagnostic Imaging in 2011. He is an honorary Professor of the Royal Veterinary College and became a Fellow of the RCVS in 2016.
Editor of Equine Veterinary Education, the official journal of the British Equine Veterinary Association and the American Association of Equine Practitioners for the past 23 years, Tim has particular interests in clinical research, clinical standards and evidence based medicine, and has published widely in the professional veterinary literature, as well as authoring and editing several textbooks. He has been a member of the RCVS Practice Standards Group since 2012.
Tim has been chair of BEVA’s Education Committee since 2014, and says that during his presidential year he is keen to continue to develop BEVA’s educational activities for members at all stages of their careers.
In particular, he says he is particularly looking forward to supporting recent graduates in equine practice with relevant CPD and mentoring. He also hopes to advance the use of evidence-based veterinary medicine, and promote quality improvement in equine practice.
Tim said: "Equine practice is continuing to change and evolve with some rapidity. An important part of my focus will be on our Equine Veterinary Horizons Project, looking at anticipated advances over the next 10-15 years, what they will mean to individual practitioners and to practices and how we can adapt to and accommodate them to best advantage."
For further information visit www.beva.org.uk.